Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center
Background. Few studies have investigated the epidemiological metabolic (dysfunction) associated with fatty liver disease (MAFLD) in China, especially among those with type 2 diabetes. Methods. We recruited 3553 patients aged 18-75 years with type 2 diabetes who underwent abdominal ultrasound and se...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2022-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2022/8429847 |
| _version_ | 1798024117893464064 |
|---|---|
| author | Conghui Guan Songbo Fu Donghu Zhen Kuan Yang Jinyang An Yapei Wang Chengxu Ma Na Jiang Nan Zhao Jinjin Liu Fang Yang Xulei Tang |
| author_facet | Conghui Guan Songbo Fu Donghu Zhen Kuan Yang Jinyang An Yapei Wang Chengxu Ma Na Jiang Nan Zhao Jinjin Liu Fang Yang Xulei Tang |
| author_sort | Conghui Guan |
| collection | DOAJ |
| description | Background. Few studies have investigated the epidemiological metabolic (dysfunction) associated with fatty liver disease (MAFLD) in China, especially among those with type 2 diabetes. Methods. We recruited 3553 patients aged 18-75 years with type 2 diabetes who underwent abdominal ultrasound and serum biochemical analyses. Patient information including demographic and anthropometric parameters was also collected. Results. Overall, 63.2% of type 2 diabetic patients had MAFLD. Among the MAFLD patients, the proportions of lean, nonobese, and obese MAFLD were 23.1%, 75.7%, and 24.3%, respectively, and the percentage of previously undiagnosed MAFLD was 42.2%. MAFLD patients were younger, had shorter diabetic duration, and had greater BMI, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting insulin, postprandial insulin, total cholesterol, and insulin resistance levels (HOMA-IR and TyG index). Liver fibrosis diagnostic panels revealed that the proportions of elevated AST (≥40 U/L) and ALT (≥40 U/L) were 7.3% and 18.5%, respectively. The distributions of AST-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) index, and nonalcoholic fatty liver disease fibrosis score (NFS) per stage were as follows: APRI—low 55.1%, indeterminate 35.3%, and high 9.5%; FIB-4—low 48.2%, indeterminate 45.3%, and high 6.5%; and NFS—low 15.0%, indeterminate 70.0%, and high 13.0%. Conclusions. MAFLD is a very common condition and generally had greater frequency of metabolic characteristics among type 2 diabetics in China. Many MAFLD patients were in the “indeterminate” or “high” stage when APRI, FIB-4, and NFS were assessed. Assessment of MAFLD should be included in the management of type 2 diabetes. |
| first_indexed | 2024-04-11T17:57:14Z |
| format | Article |
| id | doaj.art-15353bb970ee448a931edc1324dd7a1a |
| institution | Directory Open Access Journal |
| issn | 2314-6753 |
| language | English |
| last_indexed | 2024-04-11T17:57:14Z |
| publishDate | 2022-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj.art-15353bb970ee448a931edc1324dd7a1a2022-12-22T04:10:37ZengHindawi LimitedJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/8429847Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management CenterConghui Guan0Songbo Fu1Donghu Zhen2Kuan Yang3Jinyang An4Yapei Wang5Chengxu Ma6Na Jiang7Nan Zhao8Jinjin Liu9Fang Yang10Xulei Tang11Department of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyThe First Clinical Medical CollegeThe First Clinical Medical CollegeThe First Clinical Medical CollegeDepartment of EndocrinologyThe First Clinical Medical CollegeDepartment of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyDepartment of EndocrinologyBackground. Few studies have investigated the epidemiological metabolic (dysfunction) associated with fatty liver disease (MAFLD) in China, especially among those with type 2 diabetes. Methods. We recruited 3553 patients aged 18-75 years with type 2 diabetes who underwent abdominal ultrasound and serum biochemical analyses. Patient information including demographic and anthropometric parameters was also collected. Results. Overall, 63.2% of type 2 diabetic patients had MAFLD. Among the MAFLD patients, the proportions of lean, nonobese, and obese MAFLD were 23.1%, 75.7%, and 24.3%, respectively, and the percentage of previously undiagnosed MAFLD was 42.2%. MAFLD patients were younger, had shorter diabetic duration, and had greater BMI, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting insulin, postprandial insulin, total cholesterol, and insulin resistance levels (HOMA-IR and TyG index). Liver fibrosis diagnostic panels revealed that the proportions of elevated AST (≥40 U/L) and ALT (≥40 U/L) were 7.3% and 18.5%, respectively. The distributions of AST-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) index, and nonalcoholic fatty liver disease fibrosis score (NFS) per stage were as follows: APRI—low 55.1%, indeterminate 35.3%, and high 9.5%; FIB-4—low 48.2%, indeterminate 45.3%, and high 6.5%; and NFS—low 15.0%, indeterminate 70.0%, and high 13.0%. Conclusions. MAFLD is a very common condition and generally had greater frequency of metabolic characteristics among type 2 diabetics in China. Many MAFLD patients were in the “indeterminate” or “high” stage when APRI, FIB-4, and NFS were assessed. Assessment of MAFLD should be included in the management of type 2 diabetes.http://dx.doi.org/10.1155/2022/8429847 |
| spellingShingle | Conghui Guan Songbo Fu Donghu Zhen Kuan Yang Jinyang An Yapei Wang Chengxu Ma Na Jiang Nan Zhao Jinjin Liu Fang Yang Xulei Tang Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center Journal of Diabetes Research |
| title | Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center |
| title_full | Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center |
| title_fullStr | Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center |
| title_full_unstemmed | Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center |
| title_short | Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center |
| title_sort | metabolic dysfunction associated fatty liver disease in chinese patients with type 2 diabetes from a subcenter of the national metabolic management center |
| url | http://dx.doi.org/10.1155/2022/8429847 |
| work_keys_str_mv | AT conghuiguan metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT songbofu metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT donghuzhen metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT kuanyang metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT jinyangan metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT yapeiwang metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT chengxuma metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT najiang metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT nanzhao metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT jinjinliu metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT fangyang metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter AT xuleitang metabolicdysfunctionassociatedfattyliverdiseaseinchinesepatientswithtype2diabetesfromasubcenterofthenationalmetabolicmanagementcenter |